Volume 14, Number 2—February 2008
Research
Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic
M. Ruby Siddiqui*
and W. John Edmunds*
and W. John Edmunds*
Table
Total NHS costs and QALY loss (discounted at 3.5%) resulting from an influenza pandemic occurring in 30 years assuming 1918 or 1957/69 CFR*
| Treatment program | Pandemic influenza cases (millions) | Pandemic influenza deaths (millions) | Discounted NHS costs (million £) | Discounted QALY loss (millions) | Incremental cost per QALY (£) |
|---|---|---|---|---|---|
| 1918 scenario | |||||
| No intervention | 15 | 0.344 | 113 | 2.23 | |
| Treat only | 15 | 0.236 | 1,361 | 1.56 | 1,861† |
| Test-treat | 15 | 0.231 | 2,356 | 1.53 | 31,031‡ |
| 1957–69 scenario | |||||
| No intervention | 15 | 0.044 | 113 | 0.395 | |
| Treat only | 15 | 0.030 | 1,361 | 0.303 | 13,668† |
| Test-treat | 15 | 0.030 | 2,356 | 0.299 | 227,896‡ |
*NHS, National Health Service; QALY, quality-adjusted life years; CFR, case-fatality ratio.
†Cost per QALY gained over no intervention program.
‡Cost per QALY gained over treat-only program.
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.